At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results